Pfizer (PFE) closed the most recent trading day at $25.25, moving +2.35% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.21%. Meanwhile, the Dow experienced a rise of 1.03%, and the technology-dominated Nasdaq saw a decrease of 0.22%.

Prior to today's trading, shares of the drugmaker had gained 1.23% outpaced the Medical sector's loss of 0.43% and lagged the S&P 500's gain of 1.7%.

Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 4, 2026. In that report, analysts expect Pfizer to post earnings of $0.68 per share. This would mark a year-over-year decline of 12.82%. Meanwhile, the latest consensus estimate predicts the revenue to be $14.45 billion, indicating a 1.39% decrease compared to the same quarter of the previous year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $2.96 per share and revenue of $61.86 billion, which would represent changes of -8.07% and -1.16%, respectively, from the prior year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.97% fall in the Zacks Consensus EPS estimate. Pfizer currently has a Zacks Rank of #3 (Hold).

With respect to valuation, Pfizer is currently being traded at a Forward P/E ratio of 8.35. This denotes a discount relative to the industry average Forward P/E of 17.68.

The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 231, positioning it in the bottom 7% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Pfizer Inc. (PFE): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research